Leucine/sildenafil - NuSirt Biopharma

Drug Profile

Leucine/sildenafil - NuSirt Biopharma

Alternative Names: Leu Sil; NS-0300; Sildenafil/leucine - NuSirt Biopharma

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NuSirt Biopharma
  • Class Branched-chain amino acids; Erectile dysfunction therapies; Essential amino acids; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Gluconeogenesis inhibitors; SIRT1 protein stimulants; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 14 Dec 2017 Preclinical trials in Obesity in USA (PO)
  • 14 Dec 2017 NuSirt Biopharma plans a phase II trial for Obesity in January 2018 (NCT03364335)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top